Regular paper
Differential effects of neuroleptic agents on hepatic cytochrome P-450 isozymes in the male rat

https://doi.org/10.1016/0304-4165(96)00046-3Get rights and content

Abstract

We report the effects of various dopamine receptor-blocking drugs on gene and protein expression, as well as the activity of several hepatic cytochrome P-450 (CYP) enzymes in the male Sprague-Dawley rat. At equipotent doses (with respect to receptor blockade and behavioural tests), the dopamine D2-receptor selective sulpiride and remoxipride gave a conspicuous down-regulation of CYP2C11 and its associated androstenedione 16α-hydroxylation activity as well as of the CYP2C11-specific mRNA. The average immunoidentified CYP2C11 levels correlated with the CYP2C11-specific mRNA levels in all treatment groups (r=0.994), indicating a transcriptional mechanism. The CYP3A protein was also selectively down-regulated. In contrast, androstenedione 5α-reduction was significantly increased. Clozapine, a non-selective neuroleptic, gave the same effects on the steroid metabolism as sulpiride and remoxipride. In contrast, diverging effects were observed for clozapine, compared to sulpiride and remoxipride, on the immunoidentified CYP1A2, CYP2B1, and CYP3A. These proteins were elevated by clozapine, and down-regulated by sulpiride and remoxipride. Our results are of interest for the interpretation of preclinical dose ranging toxicity tests of neuroleptic agents in rats. They may also be relevant in relation to certain interactions and adverse reactions observed in the clinical use of these drugs. The down-regulation of certain CYP enzymes is most likely mediated by an interaction with the growth hormone secretion.

References (37)

  • P.G. Zaphiropoulos et al.

    Trends Pharmacol. Sci.

    (1989)
  • A. Blanck et al.

    Biochem. Pharmacol.

    (1990)
  • A. Blanck et al.

    Biochem. Pharmacol.

    (1990)
  • A. Rane et al.

    J. Steroid. Biochem. Mol. Biol.

    (1992)
  • A. Rane et al.

    Regul. Peptides Suppl.

    (1994)
  • P. Chomczynski et al.

    Anal. Biochem.

    (1987)
  • O.H. Lowry et al.

    J. Biol. Chem.

    (1951)
  • M.G. Ladona et al.

    Biochem. Pharmacol.

    (1989)
  • R.B. Taylor et al.

    J. Chromatogr.

    (1987)
  • H. Yoshioka et al.

    J. Biol. Chem.

    (1987)
  • C. Köhler et al.

    Biochem. Pharmacol.

    (1985)
  • M. Murray

    Biochem. Pharmacol

    (1992)
  • D. Pessayre et al.

    Biochem. Pharmacol.

    (1981)
  • E.T. Morgan

    Biochem. Pharmacol.

    (1991)
  • F.J. Gonzalez

    Pharmacol. Rev.

    (1988)
  • A. Mode et al.

    Endocrinology

    (1982)
  • D.J. Waxman et al.

    Mol. Endocrinol.

    (1990)
  • A. Blanck et al.

    Cancer Res.

    (1986)
  • Cited by (28)

    • Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat

      2018, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      Self-inhibition of metabolism via downregulation of CYP enzymes could be an explanation. In rats, subchronic systemic administration of selective D2 antagonists such as raclopride and other similar benzamides sulpiride and remoxipride could suppress the expression and activity of liver CYP 1A, 1B, 2B, 2C and 3A isozymes (Harkitis et al., 2015; Juřica et al., 2011; Rane et al., 1996), while repeated intracerebral raclopride administration increases CYP 2C activity (Sabová et al., 2013). In addition to modifying systemic PK, chronic administration of raclopride (via subcutaneous osmotic pump) also increases [3H]-raclopride binding sites in rat striatum (See et al., 1990).

    • The role of brain noradrenergic system in the regulation of liver cytochrome P450 expression

      2013, Biochemical Pharmacology
      Citation Excerpt :

      Hence it seems conceivable that psychotropic drugs can affect liver cytochrome P450 via neuroendocrine regulation which, in turn, may lead to metabolic drug-drug interactions. It has been shown that tricyclic antidepressants increase antipyrine clearance and accelerate the metabolism of benzphetamine and ketotifen [72,73], while phenothiazine neuroleptics inhibit steroid metabolism and produce some adverse endocrine effects [74,75]. Therefore patients receiving drugs acting on catecholaminergic systems should be carefully monitored for any possible drug interactions (concerning efficacy and safety) during polytherapy with cytochrome P450 substrates.

    • Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver

      2012, Pharmacological Reports
      Citation Excerpt :

      Some literature data indicate that neuroleptics affect CYP3A activity. Two-week treatment with clozapine in a dose substantially exceeding the pharmacological/therapeutic one (114 mg/kg/day) increased the level and activity of CYP3A1 in rats, whereas sulpiride (137 mg/kg/day) and remoxipride (31 mg/kg/ day) produced a decrease in the level of this enzyme [24]. Another study conducted by Tateishi et al. [28], who administered chlorpromazine and thioridazine in a relatively high dose of 20 mg/kg intraperitoneally (ip) for 4 days, showed that chlorpromazine did not change the total level of CYP, but induced CYP3A, whereas thioridazine reduced the total level of CYP, as well as the level and activity of CYP3A.

    • Effect of neuroleptics on cytochrome P450 2C11 (CYP2C11) in rat liver

      2011, Pharmacological Reports
      Citation Excerpt :

      The above-mentioned hormone plays a crucial role in the positive regulation of male rat CYP2C11 [1, 22, 30, 40]. The results obtained in the present study are also in line with other observations indicating down-regulation of CYP2C11 in rats after 2-week treatment with the selective antagonists of dopaminergic D2 receptors, sulpiride and remoxipride and after a 4-day treatment with the less specific dopaminergic D2 receptor-blocking neuroleptic thioridazine [33, 41]. However, the other phenothiazines tested, i.e., promazine and chlorpromazine, do not produce any significant effect on CYP2C11 activity when administered in vivo for two weeks.

    • Regulation of liver cytochrome P450 by activation of brain dopaminergic system: Physiological and pharmacological implications

      2008, Biochemical Pharmacology
      Citation Excerpt :

      The obtained results indicate that drugs affecting brain dopaminergic D2 receptors may change CYP activity in the liver. Accordingly, neuroleptics which are selective (sulpiride, remoxipride) or non-selective (phenothiazines) D2 receptor antagonists down-regulated liver CYP2C11 and CYP3A expressions after systemic administration to rats [52,53]. Hence, via stimulation (e.g. bromocriptine) or inhibition (e.g. neuroleptics) of the neuroendocrine pathways dopaminergic agents may regulate liver CYP, thus affecting the metabolism of endogenous substances (e.g. steroids) and clinically important drugs (e.g. psychotropics), which in turn modifies the final pharmacological effect.

    View all citing articles on Scopus
    View full text